Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Oligodendroglioma 1Mesothelioma, Malignant 1Gliosarcoma 1Glioma, Subependymal 1Glioma 1Glioblastoma 1Ependymoma 1Astrocytoma 1

Interventions

Magnetic Resonance Spectroscopy 9X-Rays 6Specimen Handling 6Phantoms, Imaging 6Nuclear Medicine Department, Hospital 5Temozolomide 4Carmustine 4Biopsy 4ulixertinib 2tipifarnib 2tazemetostat 2selpercatinib 2palbociclib 2olaparib 2larotrectinib 2ivosidenib 2erdafitinib 2ensartinib 2Vemurafenib 2Surgical Procedures, Operative 2Radiotherapy 2Lapatinib 2LY3023414 2Filgrastim 2Cyclophosphamide 2Congresses as Topic 2Cisplatin 2Bevacizumab 22,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide 2veliparib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Ependymoma × Etanidazole × Clear all
NCT00430079 2013-01-16

Use of EF5 to Measure the Oxygen Level in Tumor Cells of Patients Undergoing Surgery or Biopsy for Newly Diagnosed Supratentorial Malignant Glioma

National Cancer Institute (NCI)

Phase NA Terminated
48 enrolled
CNSSarcoma

Astrocytoma, Ependymoma, Glioblastoma, Glioma, Oligodendroglioma, Glioma, Subependymal, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡